Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of anlotinib combined with whole-brain radiotherapy for multiple brain metastases from non-small cell lung cancer
ChiCTR1900022093Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Intracranial progression-free survival. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR1900022093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022093.